Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Clinical Trials

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Recruiting

Conditions: Non-eligible for Autologous Stem Cell Transplantation (ASCT)
Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Daratumumab

First Posted Date: 2022-02-01

Last Posted Date: 2022-09-16

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT05218603

Locations: 🇪🇸
Hospital Quirón Sagrado Corazón, Barcelona, Spain
🇪🇸
Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain
🇪🇸
Hospital Ruber Juan Bravo 39, Madrid, Spain

and more 29 locations

Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

Completed

Conditions: Multiple Myeloma

First Posted Date: 2021-12-20

Last Posted Date: 2022-11-14

Lead Sponsor: Karin B. Ø. Dieperink

Target Recruit Count: 10

Registration Number: NCT05163405

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2

Not yet recruiting

Conditions: Neoplasms, Plasma Cell
Hematologic Diseases
Multiple Myeloma
Renal Impairment
Blood Protein Disorders
Paraproteinemias
Neoplasms by Histologic Type
Neoplasms

Interventions: Drug: Isatuximab
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2021-12-07

Last Posted Date: 2022-03-29

Lead Sponsor: Hellenic Society of Hematology

Target Recruit Count: 51

Registration Number: NCT05147493

Locations: 🇬🇷
Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece
🇬🇷
University General Hospital of Ioannina, Ioannina, Greece
🇬🇷
Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece

and more 3 locations

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Linvoseltamab
Drug: Nirogacestat
Drug: Isatuximab
Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Fianlimab
Drug: Cemiplimab
Drug: Bortezomib

First Posted Date: 2021-11-30

Last Posted Date: 2025-03-07

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 317

Registration Number: NCT05137054

Locations: 🇪🇸
Hospital Clínico Universitario de Santiago, Santiago, A Coruña, Spain
🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 35 locations

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Phase 4

Conditions: Chemotherapeutic Toxicity
Acute Lymphoblastic Leukemia, in Relapse
Minimal Residual Disease

Interventions: Drug: Bortezomib

First Posted Date: 2021-11-30

Last Posted Date: 2022-01-18

Lead Sponsor: Hospital General de Mexico

Target Recruit Count: 56

Registration Number: NCT05137860

Locations: 🇲🇽
Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico

Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

Phase 4

Not yet recruiting

Conditions: Thrombotic Thrombocytopenic Purpura, Acquired

Interventions: Drug: Bortezomib Injection

First Posted Date: 2021-11-26

Last Posted Date: 2021-11-26

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT05135442

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, (Select), China

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Bortezomib
Drug: Lenalidomide
Drug: Dexamethasone (IV)

First Posted Date: 2021-11-17

Last Posted Date: 2025-04-10

Lead Sponsor: Cancer Trials Ireland

Target Recruit Count: 54

Registration Number: NCT05123131

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪
Mater Misericordiae University Hospital, Dublin, Ireland

and more 3 locations